ES2886958T3 - Roedores que tienen un gen TMPRSS humanizado - Google Patents
Roedores que tienen un gen TMPRSS humanizado Download PDFInfo
- Publication number
- ES2886958T3 ES2886958T3 ES17709888T ES17709888T ES2886958T3 ES 2886958 T3 ES2886958 T3 ES 2886958T3 ES 17709888 T ES17709888 T ES 17709888T ES 17709888 T ES17709888 T ES 17709888T ES 2886958 T3 ES2886958 T3 ES 2886958T3
- Authority
- ES
- Spain
- Prior art keywords
- gene
- rodent
- tmprss
- humanized
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000283984 Rodentia Species 0.000 title claims abstract description 433
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 372
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 135
- 239000002773 nucleotide Substances 0.000 claims abstract description 93
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 93
- 230000001086 cytosolic effect Effects 0.000 claims abstract description 70
- 238000006467 substitution reaction Methods 0.000 claims abstract description 13
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 claims description 133
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims description 96
- 101100207058 Mus musculus Tmprss2 gene Proteins 0.000 claims description 73
- 101100099740 Homo sapiens TMPRSS11D gene Proteins 0.000 claims description 72
- 101150089613 Tmprss11d gene Proteins 0.000 claims description 72
- 101150109926 Tmprss2 gene Proteins 0.000 claims description 68
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 claims description 62
- 239000012634 fragment Substances 0.000 claims description 47
- 108700024394 Exon Proteins 0.000 claims description 35
- 102000049800 human TMPRSS2 Human genes 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 108020004705 Codon Proteins 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 28
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 206010022000 influenza Diseases 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 241000712431 Influenza A virus Species 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 124
- 241000699666 Mus <mouse, genus> Species 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 41
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 36
- 102000055733 human TMPRSS11D Human genes 0.000 description 34
- 108020005345 3' Untranslated Regions Proteins 0.000 description 31
- 102000056947 human TMPRSS4 Human genes 0.000 description 29
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 229930193140 Neomycin Natural products 0.000 description 21
- 229960004927 neomycin Drugs 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 108700028369 Alleles Proteins 0.000 description 17
- 102000035195 Peptidases Human genes 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 241000712461 unidentified influenza virus Species 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 101100099741 Mus musculus Tmprss11d gene Proteins 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 101710154606 Hemagglutinin Proteins 0.000 description 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 8
- 101710176177 Protein A56 Proteins 0.000 description 8
- 102000012479 Serine Proteases Human genes 0.000 description 8
- 108010022999 Serine Proteases Proteins 0.000 description 8
- 239000000185 hemagglutinin Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 108010051219 Cre recombinase Proteins 0.000 description 6
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 101000598058 Homo sapiens Transmembrane protease serine 11D Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 241000699729 Muridae Species 0.000 description 4
- 102100037025 Transmembrane protease serine 11D Human genes 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108010078070 scavenger receptors Proteins 0.000 description 4
- 102000014452 scavenger receptors Human genes 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108091005461 Nucleic proteins Chemical group 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- -1 that is Proteins 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 101150079978 AGRN gene Proteins 0.000 description 2
- 102100040026 Agrin Human genes 0.000 description 2
- 108700019743 Agrin Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 2
- 101000872580 Homo sapiens Serine protease hepsin Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100034801 Serine protease hepsin Human genes 0.000 description 2
- 101150115575 TMPRSS4 gene Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 241000699725 Acomys Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000700193 Calomyscus Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 101710108755 Extracellular serine protease Proteins 0.000 description 1
- 108050007261 Frizzled domains Proteins 0.000 description 1
- 102000018152 Frizzled domains Human genes 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 102000004989 Hepsin Human genes 0.000 description 1
- 108090001101 Hepsin Proteins 0.000 description 1
- 101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100027612 Kallikrein-11 Human genes 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241001046461 Lophiomys imhausi Species 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000398750 Muroidea Species 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- 241001529466 Muscardinus avellanarius Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 241001504165 Perognathus Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000605112 Scapanulus oweni Species 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000398956 Spalacidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 101710152431 Trypsin-like protease Proteins 0.000 description 1
- 241001105470 Valenzuela Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 102000014108 human airway trypsin-like protease Human genes 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108091007169 meprins Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301023P | 2016-02-29 | 2016-02-29 | |
| PCT/US2017/019574 WO2017151453A1 (en) | 2016-02-29 | 2017-02-27 | Rodents having a humanized tmprss gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2886958T3 true ES2886958T3 (es) | 2021-12-21 |
Family
ID=58264641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17709888T Active ES2886958T3 (es) | 2016-02-29 | 2017-02-27 | Roedores que tienen un gen TMPRSS humanizado |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US10070632B2 (enExample) |
| EP (2) | EP3422845B1 (enExample) |
| JP (1) | JP6980674B2 (enExample) |
| KR (2) | KR102775366B1 (enExample) |
| CN (1) | CN109068621B (enExample) |
| AU (1) | AU2017228293B2 (enExample) |
| CA (1) | CA3014645C (enExample) |
| DK (1) | DK3422845T3 (enExample) |
| ES (1) | ES2886958T3 (enExample) |
| IL (1) | IL261139B (enExample) |
| PT (1) | PT3422845T (enExample) |
| RU (1) | RU2749715C2 (enExample) |
| SG (2) | SG10202001578RA (enExample) |
| WO (1) | WO2017151453A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202001578RA (en) * | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| CA3071712C (en) * | 2017-09-29 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus and methods of use |
| HRP20210876T1 (hr) | 2018-01-26 | 2021-07-09 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen |
| SG11202011284RA (en) | 2018-07-16 | 2020-12-30 | Regeneron Pharma | Non-human animal models of ditra disease and uses thereof |
| KR20210116480A (ko) * | 2019-01-17 | 2021-09-27 | 리제너론 파마슈티칼스 인코포레이티드 | 기분 장애의 설치류 모델 |
| CN115427457A (zh) | 2020-02-10 | 2022-12-02 | 瑞泽恩制药公司 | 抗tmprss2抗体和抗原结合片段 |
| CN115161326B (zh) * | 2021-06-21 | 2024-09-24 | 百奥赛图(北京)医药科技股份有限公司 | Sost基因人源化非人动物及其构建方法和应用 |
| WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002065266A (ja) * | 2000-08-28 | 2002-03-05 | Teijin Ltd | 気道特異的トリプシン様酵素およびその利用法 |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002359781A1 (en) * | 2001-12-20 | 2003-07-09 | The Regents Of The University Of California | Triple transgenic mouse model of alzheimer's disease |
| US20050026255A1 (en) * | 2002-06-25 | 2005-02-03 | Morser John Michael | Corin, a serine protease |
| US20040132156A1 (en) * | 2002-10-04 | 2004-07-08 | Schering Aktiengesellschaft | Modified hepsin molecules having a substitute activation sequence and uses thereof |
| CA2527361A1 (en) * | 2003-06-11 | 2004-12-23 | Schering Aktiengesellschaft | Novel modified corin molecules having substitute activation sequences and uses thereof |
| US7491865B2 (en) * | 2004-08-19 | 2009-02-17 | Fred Hutchinson Cancer Research Center | Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene |
| ES2667169T3 (es) | 2004-10-19 | 2018-05-09 | Regeneron Pharmaceuticals, Inc. | Método para generar un animal no humano homocigótico para una modificación genética |
| PT2019837E (pt) * | 2006-05-23 | 2011-07-05 | Irm Llc | Compostos e composições como inibidores das proteases activadoras de canal |
| GB0821624D0 (en) * | 2008-11-26 | 2008-12-31 | Eisai London Res Lab Ltd | Assay |
| JP5851842B2 (ja) * | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| CN105861553B (zh) * | 2011-02-15 | 2020-08-14 | 再生元制药公司 | 人源化m-csf小鼠 |
| HUE035652T2 (en) | 2011-10-28 | 2018-05-28 | Regeneron Pharma | Genetically modified major histocompatibility complex mice |
| DK2663575T3 (en) | 2011-10-28 | 2014-12-15 | Regeneron Pharma | HUMANIZED IL-6 and IL-6 receptor |
| KR102113108B1 (ko) | 2011-10-28 | 2020-05-20 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스 |
| JP6446355B2 (ja) | 2012-04-16 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| AU2013278075B2 (en) * | 2012-06-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof |
| IL307969B1 (en) | 2012-09-07 | 2025-10-01 | Regeneron Pharma | Genetically modified non-human animals and methods of using them |
| CA2887706C (en) | 2012-11-05 | 2022-08-02 | Regeneron Pharmaceuticals | Genetically modified non-human animals and methods of use thereof |
| WO2014130671A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| CN109913495B (zh) | 2013-02-20 | 2022-11-25 | 瑞泽恩制药公司 | 大鼠的遗传修饰 |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| KR102211267B1 (ko) | 2013-02-22 | 2021-02-04 | 리제너론 파아마슈티컬스, 인크. | 사람화된 주요 조직적합성 복합체를 발현하는 마우스 |
| SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| CA2913732A1 (en) | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| RU2018136614A (ru) | 2013-09-23 | 2018-11-27 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные с гуманизированным геном сигнального регуляторного белка |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3071024B1 (en) | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| AU2014353347B2 (en) | 2013-11-19 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| ES2794942T3 (es) | 2014-04-08 | 2020-11-19 | Regeneron Pharma | Animales no humanos que tienen receptores Fc-gamma humanizados |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| DK3145307T3 (en) | 2014-05-19 | 2019-04-15 | Regeneron Pharma | RE-MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO |
| SG11201609638RA (en) | 2014-06-19 | 2016-12-29 | Regeneron Pharma | Non-human animals having a humanized programmed cell death 1 gene |
| PL3223605T3 (pl) | 2014-11-24 | 2021-04-19 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
| DK3466255T3 (da) | 2014-12-05 | 2021-05-03 | Regeneron Pharma | Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen |
| ES2841353T3 (es) | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
| HUE054612T2 (hu) | 2015-11-20 | 2021-09-28 | Regeneron Pharma | Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok |
| SG10202001578RA (en) | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| KR101693243B1 (ko) | 2016-06-15 | 2017-01-05 | 재단법인 한국파스퇴르연구소 | 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도 |
-
2017
- 2017-02-27 SG SG10202001578RA patent/SG10202001578RA/en unknown
- 2017-02-27 DK DK17709888.6T patent/DK3422845T3/da active
- 2017-02-27 EP EP17709888.6A patent/EP3422845B1/en active Active
- 2017-02-27 KR KR1020237003004A patent/KR102775366B1/ko active Active
- 2017-02-27 RU RU2018131152A patent/RU2749715C2/ru active
- 2017-02-27 EP EP21170433.3A patent/EP3895529A1/en active Pending
- 2017-02-27 CA CA3014645A patent/CA3014645C/en active Active
- 2017-02-27 KR KR1020187026552A patent/KR102493894B1/ko active Active
- 2017-02-27 WO PCT/US2017/019574 patent/WO2017151453A1/en not_active Ceased
- 2017-02-27 CN CN201780010404.0A patent/CN109068621B/zh active Active
- 2017-02-27 AU AU2017228293A patent/AU2017228293B2/en active Active
- 2017-02-27 ES ES17709888T patent/ES2886958T3/es active Active
- 2017-02-27 JP JP2018545182A patent/JP6980674B2/ja active Active
- 2017-02-27 PT PT177098886T patent/PT3422845T/pt unknown
- 2017-02-27 SG SG11201807038UA patent/SG11201807038UA/en unknown
- 2017-02-27 US US15/442,857 patent/US10070632B2/en active Active
- 2017-06-16 US US15/624,774 patent/US10070631B2/en active Active
-
2018
- 2018-08-02 US US16/052,700 patent/US10863729B2/en active Active
- 2018-08-13 IL IL261139A patent/IL261139B/en unknown
-
2020
- 2020-11-17 US US17/099,942 patent/US11910787B2/en active Active
-
2024
- 2024-01-16 US US18/413,096 patent/US20240147971A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2886958T3 (es) | Roedores que tienen un gen TMPRSS humanizado | |
| ES2950399T3 (es) | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos | |
| Cann et al. | Developmental expression of LC3α and β: absence of fibronectin or autophagy phenotype in LC3β knockout mice | |
| ES2703549T3 (es) | Animales no humanos que tienen un gen de un ligando inductor de la proliferación humanizado | |
| CN104837989A (zh) | 通过等位基因替代生成fmdv抗性牲畜 | |
| FI4269430T3 (fi) | Ei-ihmiseläimiä, joilla on humanisoitu signaalin säätelyproteiinigeeni | |
| KR20210005661A (ko) | 변형된 아미노펩티다제 n(anpep) 유전자를 갖는 병원체-내성 동물 | |
| ES2975416T3 (es) | Modelo humanizado de trastornos renales y hepáticos | |
| KR102783949B1 (ko) | 인간화 알부민 좌위를 포함하는 비-인간 동물 | |
| CN102653756B (zh) | 一种定向改造动物基因组特定基因的方法及其应用 | |
| WO2005003342A1 (ja) | メチル化を利用したトランスジェニック生物を作製する方法およびシステム | |
| JP2024041751A (ja) | サイトカイン産生の調節 | |
| KR20030022762A (ko) | Ｔｒｐ 유전자 파괴를 포함하는 형질전환 마우스 | |
| Min et al. | Generation of antiviral transgenic chicken using spermatogonial stem cell transfected in vivo | |
| HK1260889B (en) | Rodents having a humanized tmprss gene | |
| JP2005518800A (ja) | 構成的に活性化されたチロシンキナーゼレセプターを発現するトランスジェニック非ヒト哺乳動物 | |
| HK40057446A (en) | Rodents having a humanized tmprss gene | |
| WO2011042874A1 (en) | Visualization of proprotein convertase activity in living cells and tissues | |
| US20250049006A1 (en) | Non-human animals comprising humanized ace2 and tmprss loci | |
| RU2815514C2 (ru) | Животные, отличные от человека, содержащие гуманизированный локус альбумина | |
| JP6078383B2 (ja) | トランスジェニック非ヒト哺乳動物 | |
| JP2016518839A (ja) | Ｃｍｐ−アセチルノイラミン酸ヒドロキシラーゼタゲッティングベクター、そのベクターが導入された異種間移植用形質転換動物及びその製造方法 | |
| JP2024172058A (ja) | 発光検出方法、ドラッグデリバリー評価方法、補助剤のスクリーニング方法及び発光検出キット | |
| Naumann et al. | Transgenic Mice for a Tamoxifen-Induced, Conditional Expression of the Cre Recombinase in Osteoclasts | |
| JP2010276505A (ja) | 新規癌転移抑制剤の探索法 |